This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2040 Remove Cannabinoids Remove Pharmaceutical Related Topics
Concentrates Clinical Trials Treatment Data Compliance Extraction Oil Conditions Programs Access More Related Topics >
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.

Pharmaceutical 52
Pharmaceutical Clinical Trials Business Research and Development 52
article thumbnail

Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority

Cannabis Law Report

AUGUST 9, 2021

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today that the company was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority.

Cannabinoids 98
Cannabinoids Pharmaceutical Treatment Patients 98
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024